Wolfgang Miesbach: Teclistamab Targets the Source of Pathogenic Autoantibodies
Wolfgang Miesbach, Head of the Hemostasis and Hemophilia Center at Department of Medicine II, University Hospital Frankfurt, shared a post on LinkedIn about a recent article by Johannes Thaler et al., published in JTH, adding:
”Seven patients, seven complete remissions, and one case that should not have worked.
Two papers have just been published on teclistamab in autoantibody-mediated coagulation disorders.
The drug is a bispecific antibody approved in multiple myeloma: it links the patient’s own T cells to B-cell maturation antigen (BCMA) on plasma cells and mature B cells and destroys them, removing the source of the autoantibody instead of the autoantibody itself.
Thaler, Cihan Ay et al. (Vienna) treated seven patients off-label: acquired von Willebrand disease (2), acquired factor XI deficiency (2), catastrophic APS (3). All reached complete remission, first laboratory response after a median of 14 days, median follow-up 52 weeks.
Dobbelstein, Andreas Tiede et al. (Hannover) report acquired haemophilia A that had already defeated CyDRi, daratumumab and two infusions of anti-CD19 CAR-T cells. FVIII 104 IU/dl by day 14, inhibitor cleared, remission now beyond one year.
Some important aspects:
- Bleeding and thrombotic phenotypes responded alike, which points to the plasma cell as the common denominator.
- The bispecific worked where CAR-T had failed. BCMA reaches cells that CD20 and CD19 do not.
- No cell manufacturing and no apheresis slot: any centre with myeloma experience could deliver this.
Adverse events: hypogammaglobulinaemia in every patient, with open-ended immunoglobulin replacement, and mild cytokine release syndrome (grade 1, fever alone, controlled with antipyretics) in 3 of 7.
The question is no longer whether it works, but when to use it.”
Title: Teclistamab for the treatment of autoantibody-mediated coagulation disorders
Authors: Johannes Thaler, Karoline Gleixner, Lisbeth Eischer, Gabriel Kammerer, Joachim Rettl, Lisa Sailer, Christian Sillaber, Peter Quehenberger, Maria Theresa Krauth, Paul Knöbl, Cihan Ay, Hermine Agis

Other posts featuring Wolfgang Miesbach on Hemostasis Today.
-
Nov 8, 2026, 19:31Anna Kajaste-Rudnitski: Presenting AAV-Induced p53 Signalling in Human CNS Cells at ESGCT 26
-
Nov 8, 2026, 19:29David McIntosh: Cybersecurity Matters, but Blood Availability Remains the Bigger Challenge
-
Nov 8, 2026, 19:26Wenxue Ma: An Integrative Framework for Macrophage-Mediated Therapeutic Resistance in Cancer
-
Nov 8, 2026, 19:25Yildiz Yigit: Presenting a Polycythemia Vera Case at the MPN Subcommittee Session
-
Nov 8, 2026, 18:56Denis Oduor: Strengthening the Regulation and Delivery of Blood Transfusion and Transplantation Services
-
Nov 8, 2026, 18:28Raghavendra Rao: A Narrative Review on Chronic Venous Disease during Pregnancy
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause
-
Nov 8, 2026, 17:38Nasrin Samadi: Can a Normal Clotting Test Be Misleading?